↓ Skip to main content

Dove Medical Press

Article Metrics

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma

Overview of attention for article published in Cancer Management and Research, August 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
82 Mendeley
Title
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
Published in
Cancer Management and Research, August 2012
DOI 10.2147/cmar.s25284
Pubmed ID
Authors

James Larkin, Fisher

Abstract

The BRAF inhibitor, vemurafenib, has demonstrated improved progression-free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care in patients with advanced melanoma harboring a BRAF-V600 mutation. A BRAF-V600 mutation is identified in approximately half of patients with cutaneous melanoma, and is unequivocally a biomarker predictive of profound clinical benefit for these patients. However, acquired vemurafenib resistance is a major clinical challenge and therapy is not yet curative. A substantial body of translational research has been performed alongside clinical trials of vemurafenib, providing key insights into the molecular basis of response and resistance. This review summarizes the development of vemurafenib for the treatment of BRAF-V600 mutant melanoma and discusses how knowledge of critical signaling pathways will be applied for its optimal clinical use in future.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 4%
Unknown 79 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 19 23%
Student > Ph. D. Student 13 16%
Researcher 12 15%
Student > Bachelor 11 13%
Other 8 10%
Other 19 23%
Readers by discipline Count As %
Medicine and Dentistry 21 26%
Agricultural and Biological Sciences 19 23%
Biochemistry, Genetics and Molecular Biology 17 21%
Unspecified 9 11%
Chemistry 5 6%
Other 11 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2012.
All research outputs
#9,079,634
of 11,341,533 outputs
Outputs from Cancer Management and Research
#181
of 264 outputs
Outputs of similar age
#81,057
of 111,610 outputs
Outputs of similar age from Cancer Management and Research
#13
of 18 outputs
Altmetric has tracked 11,341,533 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 264 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,610 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.